Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Delcath Systems (DCTH)
NASDAQ:DCTH
DCTH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.70 - $16.97
Previous CloseN/A
Volume96.76K
Average Volume (3M)434.97K
Market Cap
$523.41M
Enterprise Value$281.16M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Apr 01, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.35
Shares Outstanding31,973,783
10 Day Avg. Volume293,820
30 Day Avg. Volume434,971
Standard Deviation0.20
R-Squared0.05
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)22.21
Price to Cash Flow (P/CF)-34.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit196.61
Enterprise Value/Ebitda-7.66
Forecast
1Y Price Target
$21.33Price Target Upside37.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Delcath Systems News
PremiumCompany Announcements
Delcath Systems Reports Strong 2024 Financial Performance
PremiumCompany Announcements
Delcath Systems Secures $16.3M from Warrant Exercise
PremiumCompany Announcements
Delcath Systems Reports Strong Q3 Growth and Expansion---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceDelcath presents a rare investment opportunity in biotech: growing revenues, profitability, and soon to be cash flow positive.
Market ExpansionThe potential for Hepzato to be used across multiple liver-dominant cancers and in combination with IO therapies provides substantial revenue expansion opportunity.
Product PerformancePreliminary 4Q24 and FY24 results demonstrate a continuing successful launch for Hepzato, with revenues beating expectations.
Bears Say
Commercial RisksPotential commercial risks for Delcath could affect its ability to achieve projected revenue and profitability.
CompetitionDelcath faces competition challenges, which could impact its market share and growth.
Regulatory RisksRisks associated with Delcath include commercial, clinical, regulatory, and competition challenges.
---
Ownership Overview
30.21% Insiders
4.18% Mutual Funds
28.69% Other Institutional Investors
32.97% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
DCTH FAQ
What was Delcath Systems’s price range in the past 12 months?
Delcath Systems lowest stock price was $3.70 and its highest was $16.97 in the past 12 months.
What is Delcath Systems’s market cap?
Delcath Systems’s market cap is $523.41M.
When is Delcath Systems’s upcoming earnings report date?
Delcath Systems’s upcoming earnings report date is Apr 01, 2025 which is in 38 days.
How were Delcath Systems’s earnings last quarter?
Delcath Systems released its earnings results on Nov 08, 2024. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.26.
Is Delcath Systems overvalued?
According to Wall Street analysts Delcath Systems’s price is currently Undervalued.
Does Delcath Systems pay dividends?
Delcath Systems does not currently pay dividends.
What is Delcath Systems’s EPS estimate?
Delcath Systems’s EPS estimate is >-0.01.
How many shares outstanding does Delcath Systems have?
Delcath Systems has 31,973,783 shares outstanding.
What happened to Delcath Systems’s price movement after its last earnings report?
Delcath Systems reported an EPS of $0.06 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went up 1.097%.
Which hedge fund is a major shareholder of Delcath Systems?
Currently, no hedge funds are holding shares in DCTH
---
Delcath Systems Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.33 (37.26% Upside)
$21.33 (37.26% Upside)
Blogger Sentiment
Bullish
DCTH Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 486.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $7.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 14.0%
Last 30 Days ▲ 14.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
268.68%
12-Months-Change
Fundamentals
Return on Equity
-205.01%
Trailing 12-Months
Asset Growth
-33.41%
Trailing 12-Months
Company Description
Delcath Systems
Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. It develops and commercializes CHEMOSAT and Melphalan Hydrochloride for Injection, which is a proprietary product used with the Delcath Hepatic Delivery System. The company was founded in August 1988 and is headquartered in New York, NY.
---
DCTH Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, successful center activations, and a robust financial position. However, challenges remain with seasonal treatment impacts and increased administrative expenses. The overall sentiment is cautiously optimistic.Read More>---
DCTH Stock 12 Month Forecast
Average Price Target
$21.33
▲(37.26% Upside)
Technical Analysis
Best Analysts Covering DCTH
1 Year
1 Year Success Rate
11/13 ratings generated profit
1 Year Average Return
+68.80%
reiterated a buy rating last month
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +68.80% per trade.
---